Association of peripheral blood CD36 and cardiovascular disease in non-dialysis-dependent patients with chronic kidney diseases

ZHANG Yu,YAN Yucheng,QIAN Jiaqi,DAI Huili,WANG Qin,MOU Shan,NI Zhaohui

2009-01-01

Abstract:Objective To investigate the association of peripheral blood CD36 and cardiovascular disease in non-dialysis-dependent patients with chronic kidney diseases (CKD). Methods A total of 77 non-dialysis-dependent CKD patients, including 36 at CKD stage 1—3 and 41 at stage 4-5, were included in the present study. Ten healthy subjects were taken as normal controls. The whole blood concentration of CD36 was determined by Flow Cytometer. The correlation of CD36 level with lipid, inflammation indices, intima-media thickness (IMT), carotid plaques and cardiovascular events were analyzed. CD36 levels were also observed in 10 CKD patients before and after treatment with Pravastain. Results The CD36 levels in patients at CKD stage 1—3, CKD stage 4—5 were significantly higher than that in the control subjects (476.7±191.4 vs. 68.6±12.7, 1 463.6±592.9 vs. 68.6±12.7, P<0.01], and those in the patients at CKD stage 4—5 were significantly higher than those in patients at CKD stage 1—3 (P<0.01). Pearson correlation analysis showed that CD36 level was negatively correlated with SPV (r=-0.714, P<0.01) and DV (r=-0.606,P<0.01), and positively correlated with IMT (r=0.630,P<0.01), resistance index (r=0.636, P<0.01), LVDd (r=0.421,P<0.01), LVDs (r=0.336,P<0.01), LVPWT (r=0.454,P<0.01), LVST (r=0.503,P<0.01), and LVMI (r=0.407,P<0.01), but had no relation with the EF (P>0.05). Multivaritate linear regression analysis showed that TG and GFR were stronger independent determinants of CD36 (GFR,β=-0.301, P<0.01); TC (β=0.294, P<0.01). The partial regression corrected by GFR showed that TC (r=0.231, P<0.046), TG (r=0.320, P<0.005),HDL (r=-0.237, P<0.05),and LDL (r=0.315, P<0.01)were the factors influencing CD36 level. CD36 level was significantly decreased in 10 CKD patients after treatment with Pravastatin (839.10±614.27 vs. 534.38±361.49, P<0.01). Conclusion The incidence of cardiovascular disease is high in non-dialysis CKD patients. The increased CD36 level is closely associated with dyslipidemia and atherosclerosis. Statins may decrease CD36 level and subsequently prevents the development of cardiovascular disease in CKD patients.